These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21506468)

  • 21. Economic cost for implementation of the U.S. Food and Drug Administration's Code of Federal Regulations Title 21, Part 1271 in an egg donor program.
    Baker VL; Gvakharia MO; Rone HM; Manalad JR; Adamson GD
    Fertil Steril; 2008 Sep; 90(3):537-45. PubMed ID: 17953961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of total quality principles to achieve regulatory compliance in research laboratories.
    Hynes MD
    Qual Assur; 1995 Mar; 4(1):34-40. PubMed ID: 8520863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.
    Zon R; Meropol NJ; Catalano RB; Schilsky RL
    J Clin Oncol; 2008 May; 26(15):2562-7. PubMed ID: 18390967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physician to investigator: clinical practice to clinical research--ethical, operational, and financial considerations.
    Pierre C
    J Med Pract Manage; 2008; 24(1):9-12. PubMed ID: 18754244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Good research practices: a commonsense approach to ensuring quality in research facilities.
    Herman DR; Usher RW
    Qual Assur; 1994 Dec; 3(4):355-9. PubMed ID: 7613744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishing a human research protection program in a combatant command.
    Brosch LR; Holcomb JB; Thompson JC; Cordts PR
    J Trauma; 2008 Feb; 64(2 Suppl):S9-12; discussion S12-3. PubMed ID: 18376178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative method of evaluating quality of international clinical studies in China: Analysis of site visit reports of the Clinical Research Operations and Monitoring Center.
    Chang JJ; Xu J; Fan D
    Contemp Clin Trials; 2008 Sep; 29(5):654-62. PubMed ID: 18450522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using the exception from informed consent regulations in research.
    Mosesso VN; Cone DC
    Acad Emerg Med; 2005 Nov; 12(11):1031-9. PubMed ID: 16264070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Institution/investigator-initiated clinical trials in Canada.
    Sedgeworth J; Derewlany L
    Can J Clin Pharmacol; 2006; 13(2):e236-9. PubMed ID: 16873897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Financial disclosure by clinical investigators--FDA. Final rule.
    Fed Regist; 1998 Feb; 63(21):5233-54. PubMed ID: 10177332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding Food and Drug Administration regulatory requirements for an investigational device exemption for sponsor-investigators.
    Holbein ME; Berglund JP
    J Investig Med; 2012 Oct; 60(7):987-94. PubMed ID: 22847340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trials profile: professionals and sites.
    Paschoale HS; Barbosa FR; Nita ME; Carrilho FJ; Ono-Nita SK
    Contemp Clin Trials; 2010 Sep; 31(5):438-42. PubMed ID: 20601160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individual researcher liability for clinical research on humans.
    Miller RK
    J Biolaw Bus; 2003; 6(2):8-16. PubMed ID: 14682365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer and leukemia group B clinical research associates committee.
    Price KC; Barrett BK; Roark JM
    Clin Cancer Res; 2006 Jun; 12(11 Pt 2):3642s-4s. PubMed ID: 16740800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. So You Want to Be a Principal Investigator.
    Saleh M; Naik G
    J Oncol Pract; 2018 Jun; 14(6):e384-e392. PubMed ID: 29750578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical tips for working effectively with your institutional review board.
    Schwenzer KJ
    Respir Care; 2008 Oct; 53(10):1354-61. PubMed ID: 18812000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigator financial disclosures and its effect on research subjects.
    Gibbs JN; Guagnano GA
    Food Drug Law J; 2007; 62(4):727-37. PubMed ID: 18557228
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment needs in HIV prevention trials: using beneficence to clarify sponsor-investigator responsibilities.
    Stobie M; Slack C
    Dev World Bioeth; 2010 Dec; 10(3):150-7. PubMed ID: 20002648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and quality in clinical trials. Requirements to the investigator site. European Economic Community.
    Friederichs E; Spitzer SG; Bach R
    Arzneimittelforschung; 1994 Feb; 44(2):182-4. PubMed ID: 8147953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.